Sign In
Buy ITRM
$0.0300
+0 (+0%)
At Close: Jun 30, 2026
Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025
08:00am, Friday, 31'st Jan 2025
DUBLIN, Ireland and CHICAGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infect
Iterum Therapeutics Regains Full Nasdaq Compliance
08:30am, Thursday, 21'st Nov 2024
Iterum will Continue to be Listed and Traded on the Nasdaq Stock Market Iterum will Continue to be Listed and Traded on the Nasdaq Stock Market
Iterum Therapeutics plc (ITRM) Q3 2024 Earnings Call Transcript
01:14pm, Thursday, 14'th Nov 2024
Iterum Therapeutics plc (NASDAQ:ITRM ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Louise Barrett - Senior Vice President, Legal Affairs Corey Fishman - Chief Ex
Iterum Therapeutics Reports Third Quarter 2024 Financial Results
07:00am, Thursday, 14'th Nov 2024
- - ORLYNVAH TM Approved by FDA on October 25, 2024— --Company to Host Conference Call Today at 8:30 a.m. EDT-- DUBLIN and CHICAGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq:
Iterum Therapeutics plc (ITRM) U.S. FDA Approval of ORLYNVAH Call (Transcript)
10:27am, Monday, 28'th Oct 2024
Iterum Therapeutics plc (NASDAQ:ITRM ) U.S. FDA Approval of ORLYNVAH October 28, 2024 8:30 AM ET Company Participants Louise Barrett - SVP, Legal Affairs & Secretary Corey Fishman - President, Directo
Monday, October 28, 2024, at 8:30 a.m. EDT DUBLIN and CHICAGO , Oct. 28, 2024 /PRNewswire/ -- WHO: Iterum Therapeutics plc (Nasdaq: ITRM) is focused on deliveringdifferentiated anti-infectives aimed
ORLYNVAH ™ is the first oral penem approved for use in the U.S. and the second FDA-approved treatment for uUTIs in the past two decades
Iterum Therapeutics to Present Data at IDWeek 2024
08:30am, Thursday, 10'th Oct 2024
DUBLIN and CHICAGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV an
Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit
05:00pm, Wednesday, 09'th Oct 2024
DUBLIN and CHICAGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics to
ITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down
01:05pm, Wednesday, 11'th Sep 2024
Iterum provides updates from the FDA's Antimicrobial Drugs Advisory Committee meeting on its NDA for oral sulopenem to treat adult women with uUTI.
Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference
04:30pm, Friday, 06'th Sep 2024
DUBLIN, Ireland and CHICAGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral anti
Iterum Therapeutics plc (ITRM) Q2 2024 Earnings Call Transcript
11:27am, Friday, 16'th Aug 2024
Iterum Therapeutics plc (NASDAQ:ITRM ) Q2 2024 Results Conference Call August 14, 2024 8:30 AM ET Company Participants Louise Barrett - Senior Vice President of Legal Affairs & Secretary Corey Fishman
Iterum Therapeutics Reports Second Quarter 2024 Financial Results
07:00am, Wednesday, 14'th Aug 2024
- - FDA PDUFA Action Date of October 25, 2024; Advisory Committee Meeting on September 9, 2024— - -Cash Runway into 2025, including through PDUFA Action Date-- --Company to Host Conference Call Toda
Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
04:30pm, Wednesday, 07'th Aug 2024
DUBLIN and CHICAGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV an
Iterum Therapeutics Announces Expiration and Results of Rights Offering
05:30pm, Tuesday, 06'th Aug 2024
DUBLIN and CHICAGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and
